About Dexrazoxane Hydrochloride
Class: | Anthracycline antidote and cardioprotective agent
Use: | Dexrazoxane is used to reduce the risk of cardiotoxicity associated with anthracycline chemotherapy, particularly doxorubicin, in patients with breast cancer and other malignancies. It may also be used in the treatment of extravasation of anthracycline drugs.
Adult dose: | The recommended dose is 500 mg/m² administered as an intravenous infusion over 15-30 minutes, typically given 30 minutes before the administration of the an
Drug Class
Anthracycline antidote and cardioprotective agent
Uses & Indications
Dexrazoxane is used to reduce the risk of cardiotoxicity associated with anthracycline chemotherapy, particularly doxorubicin, in patients with breast cancer and other malignancies. It may also be used in the treatment of extravasation of anthracycline drugs.
Storage Requirements
Store at room temperature (20-25°C or 68-77°F). Protect from light and keep in the original container until use.
Manufacturer & Packaging
Manufacturer: Clinigen Healthcare Ltd, UNITED KINGDOM
Package Size
1 Vial
Price & Supplier
Price in UAE: AED 1274.20
Dosage Information
Adult Dose
The recommended dose is 500 mg/m² administered as an intravenous infusion over 15-30 minutes, typically given 30 minutes before the administration of the anthracycline.
Pediatric Dose
The safety and efficacy in pediatric patients have not been established; however, if used, dosing should be determined by a healthcare professional based on individual patient factors.
Side Effects
Common side effects include nausea, vomiting, diarrhea, fatigue, and injection site reactions. Serious side effects may include myelosuppression, hypersensitivity reactions, and increased risk of secondary malignancies.
Contraindications & Precautions
Dexrazoxane is contraindicated in patients with a known hypersensitivity to the drug or any of its components. It should be used with caution in patients with pre-existing bone marrow suppression.
Important Warnings
Dexrazoxane should only be used under the supervision of a qualified healthcare professional experienced in the use of cancer chemotherapeutic agents. It may cause myelosuppression, and patients should be monitored for blood counts. There is a risk of secondary malignancies, and it should not be used in combination with certain other chemotherapeutic agents without careful consideration.
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.